Drugs / medical-grade honey
medical-grade honey
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06219018 | Dec 2024 → Dec 2026 expected | cervical intraepithelial neoplasia grade 2/3, human papilloma virus infection | Zuyderland Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | medical-grade honey | “medical-grade honey (MGH) has antiviral activity and might be able to modulate the vaginal microbiome, reduce local inflammation or directly influence the intralesional immune...” PMID 40707147 ↗ Jul 2025 |
| Known as | L-Mesitran Soft | “A total of 60 eligible women with newly histologically confirmed CIN II will receive MGH (L-Mesitran Soft) for intravaginal use for 6 months.” PMID 40707147 ↗ Jul 2025 |
| Known as | MGH | “A total of 60 eligible women with newly histologically confirmed CIN II will receive MGH (L-Mesitran Soft) for intravaginal use for 6 months.” PMID 40707147 ↗ Jul 2025 |